Advertisement

Collaboration › Details
Sangamo–Leucadia: investor conference, 201911 supply service Sangamo at Jefferies London Healthcare Conference 2019
![]() |
Period | 2019-11-21 |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
![]() |
Partner, 1st | Sangamo Therapeutics Inc. (Nasdaq: SGMO) |
Group | Sangamo (Group) | |
Partner, 2nd | Jefferies LLC | |
Group | Leucadia (Group) | |
![]() |
Product | Jefferies 2019 London Healthcare Conference |
Product 2 | cell therapy | |
Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.
Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com
Media Inquiries – Global
Aron Feingold
510-970-6000, x421
afeingold@sangamo.com
Record changed: 2019-11-27 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Sangamo (Group)
- [1] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [2] Cell Mogrify Ltd.. (4/21/20). "Press Release: Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-derived Regulatory T Cells". Cambridge & Brisbane, CA....
- [3] Sangamo Therapeutics, Inc.. (11/19/19). "Press Release: Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation". Brisbane, CA....
- [4] Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA....
- [5] Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA....
- [6] Sangamo Therapeutics, Inc.. (7/31/19). "Press Release: Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel". Brisbane, CA....
- [7] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Announces Agreement Securing Access To Large-scale, Commercial-grade Manufacturing Capacity at Brammer Bio". Brisbane, CA....
- [8] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
- [9] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data". Brisbane, CA....
- [10] Sangamo Therapeutics, Inc.. (7/23/18). "Press Release: Sangamo Therapeutics to Acquire TxCell". Richmond, CA & Valbonne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top